Positron emission testing for six cancers (brain, cervical, small cell lung, ovarian, pancreatic, and testicular)
The Centers for Medicare & Medicaid Services (CMS) requested a technology assessment by the Agency for Health Care Research and Quality (AHRQ) to evaluate the performance of 2-Fluro 2-deoxy D-glucose positron emission tomography (FDG-PET) when compared to conventional imaging (such as computed t...
| Main Author: | |
|---|---|
| Corporate Authors: | , |
| Format: | eBook |
| Language: | English |
| Published: |
Rockville, Maryland
Agency for Healthcare Research and Quality
2004, February 12, 2004
|
| Series: | Technology assessment
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The Centers for Medicare & Medicaid Services (CMS) requested a technology assessment by the Agency for Health Care Research and Quality (AHRQ) to evaluate the performance of 2-Fluro 2-deoxy D-glucose positron emission tomography (FDG-PET) when compared to conventional imaging (such as computed tomography (CT) and magnetic resonance imaging (MRI)) and when used as an adjunct to conventional imaging for patient management of six different cancers (brain, cervical, ovarian, pancreatic, small cell lung, and testicular). The Duke Evidence-based Practice Center was asked to conduct an assessment of this technology |
|---|---|
| Item Description: | Title from PDF title page |
| Physical Description: | 1 PDF file (310 pages) illustrations |